Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Clinical trial NCT03960840 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03960840
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Diffuse Large B-cell Lymphoma Acute Lymphoblastic Leukemia Large B-cell Lymphoma

Start date: 2019-06-26
Primary completion: 2027-06-30
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.